杭州博拓生物科技股份有限公司 2024年度独立董事述职报告 本人作为杭州博拓生物科技股份有限公司（以下简称"公司"）的独立董事， 在任职期间严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司独立董事管理办 法》《上海证券交易所科创板股票上市规则》等法律法规及《公司章程》《独立 董事工作细则》《独立董事专门会议工作制度》的有关规定，在 2024 年度工作 中诚实、勤勉、独立地履行独立董事职责，积极出席相关会议，认真审议董事会 各项议案，对公司重大事项发表了独立、客观、公正的独立意见，切实维护公司 和全体股东的合法权益，促进公司规范运作，充分发挥了独立董事的独立作用。 现将本人 2024 年度独立董事述职情况报告如下： 一、独立董事的基本情况 （一） 个人工作履历、专业背景以及兼职情况 1965 年出生，中国国籍，无境外永久居留权，药物分析学博士学位，浙江 工业大学药学院教授、博士生导师。1990 年 9 月至 1993 年 12 月在杭州药厂生 化药物研究所任副所长；1993 年 12 月至今任浙江工业大学药学院教授、博士生 导师。现任浙江省 ...

杭州博拓生物科技股份有限公司董事会 关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司 自律监管指引第 1 号 -- 规范运作》等要求,杭州博拓生物科技股份有限公 司(以下简称"公司")董事会,就公司在任独立董事王文明、应国清、王 亮的独立性情况进行评估并出具如下专项意见: 经核查独立董事王文明、应国清、王亮及其直系亲属和主要社会关系人 员的任职经历以及独立董事签署的相关自查文件,独立董事王文明、应国清、 王亮不存在《上市公司独立董事管理办法》第六条不得担任独立董事的情形, 在 担 任 公 司 独 立 董 事 期间, 独 立 董 事 已 严 格 遵 守 中 国 证 监 会 和 上 海 证 券 交 易 所 的 相 关 规 定, 确 保 有 足 够 的 时 间 和 精 力 勤 勉 尽 责 地 履 行 职 责, 作 出 独 立 判 断,不受公司主要股东、实际控制人或其他与公司存在利害关系的单位或个 人的影响。公司独立董事王文明、应国清、王亮符合《上市公司独立董事管 理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号 -- 规范运 作》中对独立董事独立性的相关要 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥87,886,678.18, a decrease of 35.20% compared to ¥135,626,648.51 in the same period last year[3]. - Net profit attributable to shareholders was ¥8,732,428.90, down 77.97% from ¥39,631,348.59 year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥6,374,531.32, reflecting an 83.84% decline from ¥39,439,732.29 in the previous year[3]. - The basic earnings per share were ¥0.08, down 78.95% from ¥0.38 in the same period last year[3]. - Net profit for Q1 2025 was ¥7,651,908.18, down 80.7% from ¥39,534,332.13 in Q1 2024[19]. - The company reported a total comprehensive income of ¥7,736,200.35 in Q1 2025, a decrease of 80.6% from ¥39,790,478.52 in Q1 2024[20]. Cash Flow and Assets - The net cash flow from operating activities decreased by 51.22%, amounting to ¥27,572,968.95 compared to ¥56,524,065.34 in the same period last year[3]. - Cash and cash equivalents at the end of Q1 2025 totaled ¥1,627,361,518.15, down from ¥1,765,712,542.46 at the end of Q1 2024[23]. - The company reported a net cash flow from investing activities of ¥549,667,150.86 in Q1 2025, compared to a negative cash flow of -¥158,167,545.39 in Q1 2024[23]. - The company achieved an investment cash inflow of ¥2,198,758,775.48 in Q1 2025, significantly higher than ¥10,015,205.48 in Q1 2024[23]. Expenses and Liabilities - Research and development expenses totaled ¥15,119,864.00, representing 17.20% of operating revenue, an increase of 6.40 percentage points from 10.80%[4]. - Total operating costs decreased to ¥81,933,026.26 in Q1 2025 from ¥91,142,982.46 in Q1 2024, representing a reduction of 10.0%[18]. - The total liabilities decreased from CNY 189,785,865.08 to CNY 119,507,669.73, a reduction of about 37.00%[15]. - The company reported a significant decrease in accounts payable from CNY 56,449,025.72 to CNY 42,610,289.36, a decline of approximately 24.55%[15]. Assets Overview - The total assets at the end of the reporting period were ¥2,543,737,243.69, a decrease of 2.24% from ¥2,602,132,040.91 at the end of the previous year[4]. - The company's current assets totaled CNY 1,820,532,780.18, down from CNY 1,877,922,689.10 at the end of 2024, indicating a decline of approximately 3.05%[13]. - Cash and cash equivalents increased to CNY 1,627,567,018.15 from CNY 1,590,964,931.16, reflecting a growth of about 2.33%[13]. - Accounts receivable decreased significantly from CNY 97,460,473.23 to CNY 67,092,116.03, representing a decline of approximately 31.14%[13]. - The company's equity attributable to shareholders increased slightly from CNY 2,409,476,107.01 to CNY 2,422,439,014.68, showing a growth of approximately 0.54%[16]. - The non-current assets totaled CNY 723,204,463.51, remaining relatively stable compared to CNY 724,209,351.81 at the end of 2024[14]. Market and Strategic Developments - The decline in operating revenue was primarily due to reduced government procurement in the U.S. market and cautious sales policies adopted by the company[7]. - The company reported a decrease in interest income and increased costs related to the employee stock ownership plan, contributing to the decline in net profit[7]. - The company has not reported any new product developments or market expansions during this period[11]. - There are no significant changes in the shareholder structure or any new strategic initiatives announced in the latest conference call[11]. - The total number of ordinary shareholders at the end of the reporting period was 6,212[9].

Financial Performance - The company's revenue for 2024 reached ¥559,401,884.70, representing a 26.53% increase compared to ¥442,110,404.25 in 2023[24]. - Net profit attributable to shareholders for 2024 was ¥169,515,470.99, a 59.01% increase from ¥106,605,811.85 in 2023[24]. - The net profit excluding non-recurring gains and losses for 2024 was ¥119,287,565.10, up 50.19% from ¥79,425,172.56 in 2023[24]. - Cash flow from operating activities for 2024 was ¥128,825,438.66, a slight decrease of 1.94% from ¥131,380,776.97 in 2023[24]. - Total net assets attributable to shareholders at the end of 2024 were ¥2,409,476,107.01, a decrease of 0.24% from ¥2,415,243,484.16 at the end of 2023[24]. - Basic earnings per share rose to 1.61 yuan, reflecting a 61.00% increase year-over-year, while diluted earnings per share also matched this figure[25]. - The weighted average return on equity improved to 7.03%, an increase of 2.76 percentage points from the previous year[25]. - The gross profit margin for diagnostic reagents was 49.70%, showing a slight decrease of 0.66 percentage points compared to the previous year[133]. - Operating costs increased to 263.80 million RMB, a year-on-year increase of 20.13%[129]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 10.00 CNY per 10 shares, totaling 106,416,667 CNY (including tax), which accounts for 94.17% of the net profit attributable to shareholders for 2024[6]. - The total cash dividends and share repurchase amount to 202,814,026.66 CNY, representing 119.64% of the net profit attributable to shareholders for 2024[6]. - A mid-term dividend of 5,320.83 million yuan was distributed, with a total planned dividend of 15,962.50 million yuan for 2024, accounting for 94.17% of the net profit attributable to shareholders[42][43]. Research and Development - Research and development expenses accounted for 11.36% of operating revenue, a decrease of 6.84 percentage points compared to the previous year[25]. - The total R&D investment for the current year is ¥63,574,584.74, a decrease of 21.00% compared to the previous year’s ¥80,475,253.93[88]. - The company has completed the development of four new drug testing products, with a total investment of ¥15,000,000.00 for rapid testing reagents, of which ¥3,019,702.24 was invested this period[92]. - The cumulative investment in chronic disease detection series reagents development is ¥11,627,375.41, with ongoing projects aimed at market launch[92]. - The company has developed five major diagnostic reagent product series that are at the leading level domestically or internationally, including drug abuse rapid test reagents and infectious disease multifunctional rapid test reagents[105]. Product Development and Innovation - The company launched multiple new products, including drug abuse detection reagents and clinical testing reagents, enhancing its product matrix[37][39]. - The company is focusing on the development of a microfluidic fluorescence detection platform, reallocating 60 million yuan from its fundraising for this project[40]. - The company has developed a range of diagnostic reagents for various diseases, including tests for Mycoplasma pneumoniae IgM antibodies and Legionella pneumophila[50]. - The company is expanding its offerings in the area of vitamin and hormone testing, including tests for vitamin D and cortisol levels[53]. - The company has developed a respiratory pathogen detection test with a market value of $22 million, achieving sales of approximately $5.28 million, aimed at providing timely infection information[96]. Market Expansion and Strategy - The company is actively pursuing market expansion through innovative product development and strategic technology upgrades[46]. - The company aims to enhance its global presence by establishing local production lines in countries like India and expanding into emerging markets through initiatives like the Belt and Road[168]. - The company is focusing on technological integration, with AI-assisted diagnostic systems reducing testing times by over 30%[167]. - The company is exploring potential acquisitions to enhance its market position, with a budget of $50 million allocated for this purpose[184]. - The company is committed to improving governance and internal control, optimizing production processes, and enhancing automation to reduce operational costs[173]. Compliance and Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[10]. - There are no violations of decision-making procedures regarding external guarantees[10]. - The board of directors and management confirm the accuracy and completeness of the annual report[3]. - The company is focused on ensuring compliance with internal audit requirements for 2024[198]. - The company is committed to transparency in its financial reporting and governance practices[200]. Certifications and Patents - The company has obtained CE certification for 72 products and is actively promoting 54 additional products under the EU IVDR certification project[108]. - The company has filed a total of 399 patent applications, with 269 patents granted cumulatively[80]. - The company has developed multiple new products, including a liquid sample detection device and a sample collector, which have received patent protection[81]. - The company has established a global R&D network with a headquarters in Hangzhou and a center in San Diego, focusing on local cutting-edge technology exploration[107]. - The company has successfully developed multiple reagents for quantitative detection, achieving CE certification and NMPA registration for several products[106]. Risks and Challenges - The company faces risks related to product quality control and regulatory compliance, which could adversely affect its operations[120][124]. - The company faces risks related to new product development and registration, as the POCT industry involves high technical difficulty and complex regulatory processes[112]. - The company is navigating challenges such as profit compression from centralized procurement and high-end technology barriers, while maintaining a focus on long-term value in the IVD industry[168].

公司代码：688767 公司简称：博拓生物 杭州博拓生物科技股份有限公司 2024年度内部控制评价报告 杭州博拓生物科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变 ...

杭州博拓生物科技股份有限公司 关于 2024 年度"提质增效重回报"行动方案实施情况 暨 2025 年度"提质增效重回报"行动方案 为深入贯彻落实国务院《关于进一步提高上市公司质量的意见》要求，响应 上海证券交易所《关于开展沪市公司"提质增效重回报"专项行动的倡议》，杭 州博拓生物科技股份有限公司（以下简称"公司"）于 2024 年 4 月 27 日在上海 证券交易所（www.sse.com.cn）披露了《杭州博拓生物科技股份有限公司 2024 年度"提质增效重回报"行动方案》。为进一步提高上市公司质量，保护投资者 利益，公司总结 2024 年度提质增效重回报行动方案实施情况，并结合发展实际， 制定了 2025 年"提质增效重回报"行动方案。具体如下： 一、聚焦经营主业，提升核心竞争力 公司长期专注于 POCT 试剂及仪器的研发、生产与销售，坚持"将复杂留给 自己，把便捷带给用户"的理念，持续保持高比例的研发投入。2024 年，公司 研发费用为 6,357.46 万元，占营业收入比例为 11.36%。2024 年公司新增授权专 利及著作权 39 项，其中：发明专利 9 项；国内国际市场新增认证 49 项。截至 ...

杭州博拓生物科技股份有限公司 2024 年度董事会审计委员会对会计师事务所履行监督职责 情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《国有企业、上市 公司选聘会计师事务所管理办法》和《上海证券交易所科创板上市公司自律监管 指引第 1 号——规范运作》等相关规范性文件的规定，以及公司《审计委员会议 事规则》的有关规定，现将杭州博拓生物科技股份有限公司（以下简称"公司"） 2024 年度董事会审计委员会对会计师事务所履行监督职责情况报告如下： 一、2024 年年审会计师事务所的基本情况 事务所履行监督职责的情况如下： （一）审计委员会对中汇会计师事务所的专业资质、业务能力、诚信状况、 独立性、过往审计工作情况及其执业质量等进行了严格核查和评价，认为其具备 为公司提供审计工作的资质和专业能力，能够满足公司审计工作的要求。2024 年 4 月 25 日，第三届董事会审计委员会第九次会议审议通过《关于续聘会计师事 务所的议案》，同意续聘中汇会计师事务所为公司 2024 年度财务报告及内部控制 审计机构，并同意提交董事会审议。 （二）2025 年 1 月 29 日，审计委员会与负责公司审计工作的注册会计 ...

博拓生物公告，2025年第一季度营收为8788.67万元，同比下降35.20%；净利润为873.24万元，同比下 降77.97%。 ...

博拓生物公告，2024年营业收入5.59亿元，同比增长26.53%。归属于上市公司股东的净利润1.7亿元， 同比增长59.01%。基本每股收益1.61元／股，同比增长61.00%。公司拟向全体股东每10股派发现金红利 10元(含税)，以资本公积每10股转增4股，不送红股。 ...

Financial Performance - The company achieved total operating revenue of RMB 56,058.72 million, an increase of 26.80% compared to the same period last year[4] - The net profit attributable to the parent company was RMB 17,668.33 million, reflecting a growth of 65.74% year-on-year[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 12,656.04 million, up 59.35% from the previous year[4] - Basic earnings per share increased to RMB 1.68, representing a growth of 68.00% compared to the previous year[4] - The company reported a significant increase in operating profit and total profit, both rising over 72% compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 260,763.34 million, a 1.09% increase from the beginning of the period[6] - The equity attributable to the parent company was RMB 241,625.33 million, showing a slight increase of 0.04% from the beginning of the period[6] Business Strategy - The company focused on the POCT in vitro diagnostic segment, effectively capturing customer demand and expanding both domestic and international markets[7] - The increase in profits was also attributed to improved management and production efficiency, as well as the conversion of previously unreturned orders into revenue[8] Cautionary Note - The financial data presented are preliminary and have not yet been audited, with investors advised to be cautious regarding investment risks[10]